Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 115 IDR -1.76% Market Closed
Market Cap: 52.3T IDR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one KLBF stock under the Base Case scenario is 1 842.16 IDR. Compared to the current market price of 1 115 IDR, Kalbe Farma Tbk PT is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KLBF Relative Value
Base Case
1 842.16 IDR
Undervaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
96
vs Industry
57
Median 3Y
2.7
Median 5Y
2.7
Industry
2.4
Forward
1.5
More Details
16.7
P/E
P/E
Price to Earnings
16.7
vs History
96
vs Industry
28
Median 3Y
24.7
Median 5Y
24.1
Industry
20.5
Forward
15.8
More Details
10.4
P/OCF
P/OCF
Price to OCF
10.4
vs History
96
vs Industry
36
Median 3Y
27.3
Median 5Y
21.2
Industry
15.4
More Details
15.6
P/FCFE
P/FCFE
Price to FCFE
15.6
vs History
96
vs Industry
24
Median 3Y
55.1
Median 5Y
38.9
Industry
22.6
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
96
vs Industry
31
Median 3Y
3.6
Median 5Y
3.7
Industry
2
More Details
1.5
EV/S
EV/S
Enterprise Value to Sales
1.5
vs History
96
vs Industry
60
Median 3Y
2.5
Median 5Y
2.5
Industry
2.5
Forward
1.4
More Details
4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4
vs History
96
vs Industry
48
Median 3Y
6.2
Median 5Y
6.1
Industry
4.9
More Details
12.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.1
vs History
96
vs Industry
28
Median 3Y
18.5
Median 5Y
17.4
Industry
12.6
Forward
9.8
More Details
12.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.1
vs History
96
vs Industry
32
Median 3Y
18.5
Median 5Y
17.4
Industry
15.6
Forward
11.5
More Details
9.6
EV/OCF
EV/OCF
Enterprise Value to OCF
9.6
vs History
96
vs Industry
38
Median 3Y
25.1
Median 5Y
20.2
Industry
13.9
More Details
13.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13.4
vs History
96
vs Industry
27
Median 3Y
38.7
Median 5Y
35.7
Industry
17.7
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
96
vs Industry
33
Median 3Y
3.6
Median 5Y
3.6
Industry
1.8
More Details

Multiples Across Competitors

KLBF Competitors Multiples
Kalbe Farma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Kalbe Farma Tbk PT
IDX:KLBF
51.5T IDR 1.6 16.7 12.1 12.1
US
Eli Lilly and Co
NYSE:LLY
783.4B USD 17.4 74 43 47.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
389.2B USD 4.4 27.7 13 17
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.5 21.6 14.2 16.2
CH
Roche Holding AG
SIX:ROG
233.4B CHF 4 20.3 11.3 13.4
UK
AstraZeneca PLC
LSE:AZN
173.2B GBP 4.1 31.7 126.6 193.4
US
Merck & Co Inc
NYSE:MRK
223.1B USD 3.5 13 8.8 10.4
CH
Novartis AG
SIX:NOVN
196.7B CHF 4.3 18.6 11.3 14.4
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
142.8B USD 2.2 17.8 8.5 12.1
P/E Multiple
Earnings Growth PEG
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average P/E: 26.8
16.7
12%
1.4
US
Eli Lilly and Co
NYSE:LLY
74
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.7
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
21.6
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.3
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
31.7
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
CH
Novartis AG
SIX:NOVN
18.6
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBITDA: 396.6
12.1
17%
0.7
US
Eli Lilly and Co
NYSE:LLY
43
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.6
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.8
9%
1
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBIT: 1 700.9
12.1
11%
1.1
US
Eli Lilly and Co
NYSE:LLY
47.4
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
16%
1
CH
Roche Holding AG
SIX:ROG
13.4
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.4
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
CH
Novartis AG
SIX:NOVN
14.4
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
KLBF intrinsic value, competitors valuation, and company profile.
DCF Valuation
KLBF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KLBF stock valuation using valuation multiples.
Wall Street Estimates
KLBF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KLBF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.